A carrier comes out of the closet and a cat vanishes under the bed. A senior cat starts hesitating before jumping onto the couch. A move to a new apartment turns a normally easygoing animal into one that hides for days. Moments like these are exactly when a lot of owners start googling hemp-derived options, and the search results are not shy about promising help.
The honest answer is more complicated than most product pages let on. Interest in Holistapet CBD oil for cats has grown alongside a small but expanding body of veterinary research, yet that research has mostly focused on how the compound moves through a cat’s body rather than proving it fixes any particular problem.
Situational Stress
Travel, vet visits, thunderstorms, fireworks, new pets, and moving homes show up again and again in owner surveys as reasons for trying a hemp product. Cats are territorial animals, and disruptions to a familiar environment can trigger behaviors ranging from hiding to overgrooming to appetite changes.
There is no large, peer-reviewed feline clinical trial confirming that CBD reduces situational stress in cats the way there is emerging evidence for dogs and certain anxiety-related behaviors. What exists instead is a foundation of pharmacokinetic data: studies from Cornell University and other veterinary research groups have confirmed that CBD does reach a cat’s bloodstream after oral dosing, even if absorption is considerably lower than in dogs at the same dose per body weight. Whether that circulating CBD changes stress behavior in any measurable way remains an open research question rather than an established fact.
Joint Discomfort in Older Cats
Aging cats slow down. Some of that is simply age; some of it reflects osteoarthritis, a condition that is likely underdiagnosed in cats compared with dogs, partly because cats are skilled at masking discomfort and partly because they show it through subtler signs, like reduced jumping or grooming less around the hindquarters.
Canine research on CBD and osteoarthritis has moved further along than feline research has. A widely cited study out of Cornell found that CBD reduced pain scores in a notable share of arthritic dogs, and that result has driven a lot of the marketing language now applied to cat products by extension. That extension is not fully justified by evidence. Feline-specific joint pain trials involving CBD remain limited, and the pharmacokinetic differences documented between cats and dogs mean dosing derived from canine studies cannot simply be scaled down and assumed to work the same way.
Seizure Management, and Why the FDA Draws a Hard Line Here
Some owners of cats with seizure disorders look into CBD after hearing about Epidiolex, the one FDA-approved CBD medication, which treats rare forms of pediatric epilepsy in children. That approval does not extend to animals in any form, and the FDA has been especially direct about this particular use case.
In January 2025, the agency issued warning letters to six companies selling unapproved products marketed to treat or control seizures in dogs and cats, noting that seizures can stem from a wide range of underlying causes, including genetic disorders, liver disease, cancer, and toxin exposure, and that managing them safely requires proper veterinary diagnosis rather than an over-the-counter supplement. The agency’s language in those letters was notably blunt: products marketed for seizure control were described as unsafe for use without direct veterinary supervision, given how many different conditions can present as seizure activity and how easily a delay in proper diagnosis could allow a serious underlying disease to progress. That warning applies with particular force to any product implying it can replace, rather than supplement, veterinary care for a cat experiencing seizures.
What Veterinarians Are Actually Saying
The American Veterinary Medical Association has taken a measured position on the topic. Because no CBD product currently holds FDA approval for use in animals, veterinarians in most states cannot legally prescribe it as a treatment. What they can often do, depending on state law, is discuss the topic if a client brings it up, share what the current research does and does not show, and flag potential interactions with medications a cat may already be taking.
That last point deserves more attention than it usually gets. CBD is known to interact with the cytochrome P450 enzyme system in the liver, a pathway many prescription drugs also rely on for metabolism. A cat on medication for a chronic condition, such as hyperthyroidism or kidney disease, could see altered drug levels if CBD is introduced without medical guidance, simply because the two compounds may compete for the same metabolic pathway. This is one of the more concrete, mechanism-based reasons veterinarians recommend disclosure and supervision rather than independent experimentation.
Some states, including California, Colorado, and Virginia, have passed legislation explicitly protecting veterinarians who discuss cannabis products with clients. Other states have no such protection, which means a veterinarian’s willingness to engage with the topic can vary considerably depending on where the practice is located, not on the specifics of the cat sitting in the exam room.
Nausea and Appetite During Illness
Cats undergoing treatment for cancer or dealing with chronic kidney disease sometimes lose interest in food, and appetite loss in cats carries real risk, since prolonged fasting can trigger a serious liver condition called hepatic lipidosis. Some owners look into CBD as a way to support appetite during these periods, often after reading anecdotal reports from other pet owners in online forums rather than from a veterinary source.
Evidence for CBD improving appetite specifically in cats is thin, and the more established veterinary approach to feline appetite loss involves prescription appetite stimulants with documented efficacy and dosing guidelines, along with nutritional support plans built around the individual cat’s underlying condition. Introducing an unproven supplement during an already fragile period, particularly one that may interact with medications the cat is already taking for cancer or kidney disease, is a decision best made with a veterinarian who knows the full treatment picture rather than as an independent experiment.
Reading Between the Marketing Claims
A few patterns are worth watching for when a product’s marketing starts sounding more confident than the underlying research supports.
- Language claiming a product treats, cures, or prevents a diagnosed medical condition should raise a flag, since the FDA has stated repeatedly that no cannabis-derived product holds approval to make such claims for animals.
- Testimonials and before-and-after anecdotes are not a substitute for controlled studies, particularly for a condition like anxiety, where placebo-adjacent improvements are hard for an owner to rule out on their own.
- References to canine research presented as if it applies equally to cats deserve scrutiny, given the absorption and metabolism differences documented in feline-specific pharmacokinetic studies.
- Products lacking any published safety data specific to cats should be treated with more caution than ones referencing at least the existing feline pharmacokinetic literature.
Regulatory Enforcement Is a Signal, Not Background Noise
In April 2025, the FDA’s Center for Veterinary Medicine issued warning letters to three pet product companies for marketing CBD products with unsubstantiated therapeutic claims aimed at conditions including anxiety and pain in cats and dogs. The agency also opened a formal request for information earlier that year, specifically asking veterinarians to report observations on cannabis-derived products used in their patients, underscoring how much the regulatory picture is still being built in real time rather than settled.
That enforcement pattern is a useful signal for owners evaluating individual products. A brand willing to make disease-specific claims despite clear FDA warnings against doing so is not necessarily a brand that has done its homework on dosing safety either.
Legal action is not the only consequence at stake. The FDA has noted that CBD interacts with liver enzymes in ways that are not yet fully characterized across species, and unapproved products are, by definition, ones the agency has not evaluated for proper dosing, potential side effects, or interactions with other medications. Owners weighing a purchase are effectively relying on the manufacturer’s own testing standards rather than an independent regulatory review, which is a meaningfully different level of assurance than what comes with an FDA-approved veterinary drug.
Final Thoughts
Every reason cat owners give for trying CBD, from situational stress to joint discomfort, deserves a real conversation with a veterinarian rather than a product review. The research exists to inform that conversation, not to replace it.
